Back to Search
DAVID SHER, MD
MD
Radiation Oncology Physician
NPI: 1326028648IndividualAccepts Medicare
Specialties, Licenses & Credentials
Radiation Oncology PhysicianPrimary
Radiology — Radiation Oncology
Code: 2085R0001X
223229(MA)
CMS Specialties
PrimaryRADIATION ONCOLOGY
Education
HARVARD MEDICAL SCHOOL
Class of 2003
Research & Publications (20)
Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
PMID 19036418·Urology·2009
8-other
Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
PMID 18963542·Int J Radiat Oncol Biol Phys·2009
8-other
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
PMID 19541793·Ann Oncol·2009
8-other
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
PMID 18231723·J Neurooncol·2008
8-other
Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis.
PMID 17967514·Int J Radiat Oncol Biol Phys·2008
4-observational
Quantification of mediastinal and hilar lymph node movement using four-dimensional computed tomography scan: implications for radiation treatment planning.
PMID 17920783·Int J Radiat Oncol Biol Phys·2007
8-other
A hydra with many heads: protein and polypeptide toxins from hydra and their biological roles.
PMID 19306890·Toxicon·2009
6-review
Osmotically driven prey disintegration in the gastrovascular cavity of the green hydra by a pore-forming protein.
PMID 17679608·FASEB J·2008
7-preclinical
Toxic polypeptides of the hydra--a bioinformatic approach to cnidarian allomones.
PMID 15904682·Toxicon·2005
7-preclinical
Hydralysins, a new category of beta-pore-forming toxins in cnidaria.
PMID 15824108·J Biol Chem·2005
7-preclinical
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
PMID 19556425·Blood·2009
3-trial
A pharmacological solution for a conspecific conflict: ROS-mediated territorial aggression in sea anemones.
PMID 18353415·Toxicon·2008
7-preclinical
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
PMID 18981008·Clin Cancer Res·2008
3-trial
Survival after liver transplantation for hepatoblastoma: a 2-center experience.
PMID 18970927·J Pediatr Surg·2008
4-observational
The evolutionary origin of the Runx/CBFbeta transcription factors--studies of the most basal metazoans.
PMID 18681949·BMC Evol Biol·2008
7-preclinical
Expulsion of symbiotic algae during feeding by the green hydra--a mechanism for regulating symbiont density?
PMID 18596972·PLoS One·2008
7-preclinical
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
PMID 18297531·Leuk Lymphoma·2008
8-other
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer.
PMID 17869019·Int J Radiat Oncol Biol Phys·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 55 FRUIT COX 302, MASSACHUSETTS GENERAL HOSPITAL
BOSTON, MA 02114 - Phone
- (617) 726-8650
Quick Facts
- NPI
- 1326028648
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 23
- Publications
- 20
Are you this provider?
Claim Your Profile